Biotechnology - Biotechnology, Metabolics


Current filters:


Popular Filters

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint

SOBI’s Kiobrina pivotal Ph III study fails to meet primary endpoint


Stockholm-based Swedish Orphan Biovitrum has released disappointing top-line results from a Phase III…

BiotechnologyKiobrinaMetabolicsResearchSwedish Orphan Biovitrum

Brazil’s Cristalia gains ANVISA approval for production of biosimilar drugs


The Brazilian drugmaker Cristalia has just taken another step towards its goal of producing biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyBrazilCristaliaEnbrelHerceptinMetabolicsNorditropinOncologyProductionRegulationSouth America

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech

Novo Nordisk expands HEPtune drug delivery deal with Caisson Biotech


Caisson Biotech, a wholly-owned subsidiary of Heparinex and owner of a patented heparosan-based drug…

BiotechnologyCaisson BiotechDiabetesInflammatory diseasesLicensingMetabolicsNovo Nordisk

NPS Pharma files BLA for Natpara in hypoparathyroidism


US biotech company NPS Pharmaceuticals has submitted its Biologic License Application to the US Food…

BiotechnologyMetabolicsNatparaNorth AmericaNPS Pharmaceuticals

Orexigen updates on obesity drug filing plans


US biopharma company Orexigen Therapeutics (Nasdaq: OREX) yesterday (August 7) announced its plan to…

BiotechnologyContraveEuropeFinancialMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

Plandai's upcoming weight loss study primed to outperform competing trials, say analysts


With a product that likely has the highest nutrient absorption rate into the bloodstream (bioavailability)…

BiotechnologyMetabolicsPhytofarePlandai BiotechnologyResearch

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research


Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

OPKO Health to acquire PROLOR Biotech in $480 million stock deal


Continuing on its acquisitive path, US drugmaker OPKO Health (NYSE: OPK) has signed a definitive agreement…

BiotechnologyMergers & AcquisitionsMetabolicsOPKO HealthPharmaceuticalPROLOR Biotech

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X


In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

FDA advisory gives thumbs down for Zogenix' Zohydro for chronic pain; EU label extension for Genzyme's Thyrogen


Shares of USA-based Zogenix (Nasdaq: ZGNX) plummeted 33.5% to $1.57 in after-hours trading on Friday…

BiotechnologyEuropeGenzymeMetabolicsNeurologicalNorth AmericaPharmaceuticalRegulationSanofiThyrogenZogenixZohydro

Vivus plummets as early sales of obesity drug Qsymia disappoint


US biopharma company Vivus (Nasdaq: VVUS) saw its shares plunge 24% to $11.38, after reporting third-quarter…


AstraZeneca aligns with Regulus for microRNA therapeutics


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US biotech firm Regulus Therapeutics have signed…

AstraZenecaBiotechnologyCardio-vascularLicensingMetabolicsPharmaceuticalRegulus Therapeutics

Arrowhead Research Corp improving focus, say Edison analysts


Last year's acquisition of Roche's RNAi (RNA interference) business (The Pharma Letter October 25, 2011)…

AdipotideAnti-viralsArrowhead ResearchBiotechnologyFinancialMetabolicsOncologyResearch

Low-dose Ampyra fails in multiple sclerosis study, says Acorda


USA-based biotech firm Acorda Therapeutics (Nasdaq: ACOR) has announced top line results from a post-marketing…

Acorda TherapeuticsAmpyraBiotechnologyMetabolicsNeurologicalPharmaceuticalResearch

Rhythm raises $25 million to fund diabetes and obesity drugs development


Rhythm raises $25 million to fund diabetes and obesity drugs development

BiotechnologyDiabetesFinancialIpsenMetabolicsResearchRhythm Pharmaceuticals

UK's Proximagen boosted by US lorcaserin news with respect to its own obesity drug candidate


UK-based biotechnology firm Proximagen (AIM: PRX) saw its shares leap 20.1% to 257.5 pence, on the back…


Arena Pharma gets positive FDA panel vote for obesity drug; prophylactic Truvada backed


USA-based Arena Pharmaceuticals (Nasdaq: ARNA) and Japanese licensing partner Eisai (TYO: 4523) got a…

Anti-viralsArena PharmaceuticalsBiotechnologyEisaiGilead ScienceslorcaserinLorquessMetabolicsNorth AmericaPharmaceuticalRegulationTruvada



Back to top